Cyclooxygenase Inhibitors

• 

  Subject Areas on Research

  • 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. 
  • A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. 
  • A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. 
  • A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. 
  • A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. 
  • Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. 
  • Adsorption of clofibric acid and ketoprofen onto powdered activated carbon: effect of natural organic matter. 
  • Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents. 
  • Applying the neoadjuvant paradigm to ductal carcinoma in situ. 
  • Aspartate release from rat hippocampal synaptosomes. 
  • Aspirin and dry eye? 
  • Aspirin and reproductive outcomes. 
  • Aspirin in cardiovascular disorders. What is the optimum dose? 
  • Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. 
  • Barrett's esophagus in 2008: an update. 
  • Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. 
  • COX-2 inhibitors in rheumatoid arthritis. 
  • COX-2 inhibitors. 
  • COX-2-derived prostacyclin modulates vascular remodeling. 
  • Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition. 
  • Celecoxib (celebrex) increases canine lower esophageal sphincter pressure. 
  • Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. 
  • Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. 
  • Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. 
  • Characterization of two labor-induced genes, DSCR1 and TCTE1L, in the pregnant ovine myometrium. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Clinical applications of antiplatelet therapy. 
  • Combined modality treatment for rectal cancer. 
  • Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond. 
  • Cyclooxygenase (COX) inhibitors and the intestine. 
  • Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. 
  • Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. 
  • Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis. 
  • Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). 
  • Diagnostics for aspirin resistance. 
  • Differential regulation of renin and Cox-2 expression in the renal cortex of C57Bl/6 mice. 
  • Do NSAIDs interfere with the cardioprotective effects of aspirin? 
  • Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. 
  • E-prostanoid-3 receptors mediate the proinflammatory actions of prostaglandin E2 in acute cutaneous inflammation. 
  • Effect of cyclooxygenase and lipoxygenase products on pulmonary function in group B streptococcal sepsis. 
  • Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. 
  • Effects of 9, 12, 15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on platelet aggregation. 
  • Effects of 9,12,15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on the platelet aggregation. 
  • Effects of the cyclooxygenase inhibitor meloxicam on recovery of ischemia-injured equine jejunum. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. 
  • Impact of hypocapnia and cerebral perfusion on orthostatic tolerance. 
  • Impact of medication therapy discontinuation on mortality after myocardial infarction. 
  • In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. 
  • Increased formation of thromboxane in vivo in humans with mastocytosis. 
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. 
  • Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. 
  • Interaction of salicylate and ibuprofen with the carboxylic acid: CoA ligases from bovine liver mitochondria. 
  • Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. 
  • Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. 
  • Ionotropic glutamate receptor subtypes activate c-fos transcription by distinct calcium-requiring intracellular signaling pathways. 
  • Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam. 
  • Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. 
  • Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. 
  • New treatments for rheumatoid arthritis. 
  • Nonsteroidal antiinflammatory drug use among patients with GI bleeding. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Ozone exposure modifies prostaglandin biosynthesis in perfused rat lungs. 
  • Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARalpha-mediated pathway. 
  • Potentiation of calcium levels by extracellular arachidonic acid in nuclei isolated from macrophages stimulated with receptor-recognized forms of alpha(2)-macroglobulin. 
  • Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. 
  • Prostacyclin protects against elevated blood pressure and cardiac fibrosis. 
  • Pulmonary vascular and airway responses to endothelin-1 are mediated by different mechanisms in the cat. 
  • Pyridazinones as selective cyclooxygenase-2 inhibitors. 
  • Racial/ethnic variations in non-steroidal anti-inflammatory drug (NSAID) use among patients with osteoarthritis. 
  • Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. 
  • Reduced spontaneous relaxation in immature guinea pig airway smooth muscle is associated with increased prostanoid release. 
  • Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery: a randomized, double-blind, placebo-controlled, parallel-group trial. 
  • Reduction of spinal PGE2 concentrations prevents swim stress-induced thermal hyperalgesia. 
  • Relaxation of guinea pig trachealis during electrical field stimulation increases with age. 
  • Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • Role of thromboxane A2 in the induction of apoptosis of immature thymocytes by lipopolysaccharide. 
  • Salt restriction leads to activation of adult renal mesenchymal stromal cell-like cells via prostaglandin E2 and E-prostanoid receptor 4. 
  • Substituted 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-ones as potential antiinflammatory agents. 
  • Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors. 
  • Synthesis of intracellular histamine in platelets is associated with activation of protein kinase C, but not with mobilization of Ca2+. 
  • Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). 
  • The coxib story: some lessons and more questions. 
  • The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties. 
  • The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 
  • The effect of cyclooxygenase-2 inhibition on acute and chronic donor-site pain after spinal-fusion surgery. 
  • The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. 
  • The in vitro reversal of histamine-induced vasodilation in the human internal mammary artery. 
  • The use of analgesics in the management of pain in rheumatic diseases. 
  • Therapy of rheumatoid arthritis: new developments and trends. 
  • Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. 
  • Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. 
  • Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants. 
  • Will we be able to repair osteoarthritic joints? New drugs and surgical techniques for cartilage problems.